Skip to main content
Clinical Trials/DRKS00027805
DRKS00027805
Completed
Not Applicable

Evaluation of risk factors for the development of diabetic retinopathy (DR) in patients with type 2 diabetes: comprehensive analysis with optical coherence tomography (OCT), VEGF and biomarkers of inflammation - OCT-VEGF II

GWT TUD GmbH0 sites32 target enrollmentJanuary 18, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
MedDRA 10012689MedDRA 10012688
Sponsor
GWT TUD GmbH
Enrollment
32
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 18, 2022
End Date
June 18, 2021
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Written informed consent
  • Patients with type 2 diabetes mellitus (T2DM) for whom datasets from the previous studies are available
  • Ability to understand and follow study\-related instructions

Exclusion Criteria

  • Acute infection within 14 days prior to screening
  • Acute inflammatory disease within 14 days prior to screening or current chronic inflammatory disease
  • Pre\-existing autoimmune disease
  • Treatment with immune suppressive drugs within 14 days prior to screening
  • Systemic treatment with glucocorticoids within 14 days prior to screening
  • Myocardial infarction or stroke within 1 year before inclusion
  • Surgeries (including intravitreal injections) within the previous 3 months
  • Oncological disease within the previous 5 years
  • Women who are pregnant or breast\-feeding

Outcomes

Primary Outcomes

Not specified

Similar Trials